Avalo Therapeutics (NASDAQ:AVTX) Insider Mittie Doyle Sells 1,450 Shares of Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX) insider Mittie Doyle sold 1,450 shares of Avalo Therapeutics stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $18.00, for a total value of $26,100.00. Following the sale, the insider owned 51,776 shares in the company, valued at $931,968. This represents a 2.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mittie Doyle also recently made the following trade(s):

• On Monday, April 6th, Mittie Doyle sold 3,970 shares of Avalo Therapeutics stock. The stock was sold at an average price of $18.01, for a total value of $71,499.70.
• On Wednesday, April 1st, Mittie Doyle sold 679 shares of Avalo Therapeutics stock. The stock was sold at an average price of $16.00, for a total value of $10,864.00.

Avalo Therapeutics Price Performance

Avalo Therapeutics stock opened at $18.00 on Friday. Avalo Therapeutics, Inc. has a 12 month low of $4.53 and a 12 month high of $24.27. The company has a fifty day moving average price of $15.83 and a two-hundred day moving average price of $16.09. The company has a market cap of $946.26 million, a PE ratio of -3.30 and a beta of 0.83.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.02. Equities research analysts anticipate that Avalo Therapeutics, Inc. will post -2.58 earnings per share for the current year.

Hedge Funds Weigh In On Avalo Therapeutics

Institutional investors have recently bought and sold shares of the stock. UBS Group AG increased its holdings in shares of Avalo Therapeutics by 956.9% during the 4th quarter. UBS Group AG now owns 477,816 shares of the company’s stock worth $8,677,000 after purchasing an additional 432,608 shares during the period. Moody Aldrich Partners LLC bought a new stake in shares of Avalo Therapeutics in the fourth quarter valued at about $2,419,000. Cantor Fitzgerald L. P. bought a new stake in shares of Avalo Therapeutics in the third quarter valued at about $1,083,000. Nan Fung Trinity HK Ltd. acquired a new stake in Avalo Therapeutics during the fourth quarter worth about $3,432,000. Finally, Boothbay Fund Management LLC grew its position in Avalo Therapeutics by 1,916.6% during the third quarter. Boothbay Fund Management LLC now owns 228,297 shares of the company’s stock worth $2,902,000 after buying an additional 216,976 shares in the last quarter. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Analyst Upgrades and Downgrades

AVTX has been the subject of a number of analyst reports. Bank of America began coverage on Avalo Therapeutics in a research report on Friday, June 12th. They set a “buy” rating and a $35.00 price target for the company. Mizuho raised their price target on Avalo Therapeutics from $39.00 to $45.00 and gave the company an “outperform” rating in a report on Thursday, May 14th. Piper Sandler restated an “overweight” rating and set a $60.00 price objective (up from $48.00) on shares of Avalo Therapeutics in a research note on Monday, May 11th. Wedbush reduced their price objective on shares of Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating for the company in a report on Thursday, May 14th. Finally, Citigroup reiterated an “outperform” rating on shares of Avalo Therapeutics in a research report on Wednesday, May 6th. Twelve research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $46.67.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.